EUVIMEDEUVIMED entdecken
Crossref

Anti-VGLUT2 autoantibodies in neurological diseases

Merle Corty, Friederike A Arlt, Kathrin Borowski, Stephanie Wernick, Madeleine Scharf, Fabian A Piecha, Claudia Steen, Philipp Oehler, Maria Buthut, Moritz Krill, Johann-Philipp Zöllner, Tammo Krafft und 18 weitere

Brain, Behavior, and Immunity · 2025

DOI: 10.1016/j.bbi.2025.06.014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, Behavior, and Immunity, 2025. Verfasst von Merle Corty und 29 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Immunological Laboratory Prof. h.c. (RCH) Dr. med. Winfried Stöcker, Groß Grönau, Germany. Hauptthemen laut MEDLINE: Autoantibodies, Nervous System Diseases, Vesicular Glutamate Transport Protein 2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autoantibodies are important biomarkers for the diagnosis of autoimmune diseases that help to determine treatment strategies and to understand disease pathology. Despite the increasing numbers of neuronal autoantibody discoveries, there are still patients presenting with neurological autoimmune diseases and so far uncharacterized autoantibodies. Between 12/2016 and 06/2024, we collected sera of 314 patients with a distinct uncharacterized IgG pattern in neuronal tissue indirect immunofluorescence assay (IIFA). By immunoprecipitation and mass spectrometry we identified vesicular glutamate transporter 2 (VGLUT2) as the autoantibody target and confirmed it in sera of 285/314 patients by recombinant IIFA with VGLUT2-expressing HEK293 cells, competitive inhibition assays and colocalization studies with a commercial antibody. The main diagnoses available of 87/285 patients (mean age 58, range 1-92) were encephalitis 25/87, dementia/cognitive impairment 17/87 and polyneuropathy 16/87. Detailed clinical data of 18 patients were collected retrospectively. The major symptoms of those index patients (mean age 56, range 2-78) involved cognitive changes (10/18) including memory impairment, aphasia and disorientation as well as sensorimotor disturbances (9/18) and gait abnormalities (9/18), accompanied by visual impairments (8/18). (Poly)neuropathy was observed in 10/18 cases. The majority of the anti-VGLUT2 index patients had coexisting diabetes mellitus type 2 or other chronic multisystem disorders. In 8/12 index patients, immunotherapy had beneficial effects, although only slight improvements could be obtained in most of the cases. All 17 analyzed index patient sera recognized a cytoplasmic epitope between amino acid 520-564 of VGLUT2, determined by immunoblot with recombinant antigen fragments. Anti-VGLUT2 autoantibody-associated neurological diseases may represent a new type of autoimmune disorders that might benefit from immunomodulatory treatment and predominantly manifests with encephalitis, cognitive deficits and neuropathy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AutoantibodiesNervous System DiseasesVesicular Glutamate Transport Protein 2HumansMiddle AgedMaleFemaleAgedAdultHEK293 CellsAged, 80 and overAdolescentYoung AdultChildChild, PreschoolInfantAutoimmune DiseasesRetrospective StudiesImmunoglobulin GBiomarkersEncephalitisExcitatory Amino Acid Transporter 2

Stichwörter der Autor:innen

AutoantibodyAutoimmune dementiaAutoimmune encephalitisImmunotherapyPolyneuropathyVGLUT2

Substanzen

AutoantibodiesVesicular Glutamate Transport Protein 2Immunoglobulin GBiomarkersSLC1A2 protein, humanExcitatory Amino Acid Transporter 2

Autor:innen und Institutionen

  • Clinical Immunological Laboratory Prof. h.c. (RCH) Dr. med. Winfried Stöcker, Groß Grönau, Germany.
  • German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany; Department of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt…
  • Institute for Experimental Immunology, affiliated with EUROIMMUN Medizinische Labordiagnostika AG, Seekamp 31, 23560 Luebeck, Germany.
  • LADR Laborzentrum Nord, Flintbek, Germany.
  • St. Joseph Hospital Berlin, Department for sick children, Berlin, Germany.
  • Department of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Berlin, Berlin, Germany.

Zitieren

APA

Corty, M., Arlt, F. A., Borowski, K., Wernick, S., Scharf, M., Piecha, F. A., Steen, C., Oehler, P., Buthut, M., Krill, M., Zöllner, J. P., Krafft, T., Markewitz, R., Radzimski, C., Denno, Y., Probst, C., Teegen, B., Grefkes, C., Knake, S., …, & Miske, R. (2025). Anti-VGLUT2 autoantibodies in neurological diseases. Brain, Behavior, and Immunity. https://doi.org/10.1016/j.bbi.2025.06.014

Vancouver

Corty M, Arlt FA, Borowski K, Wernick S, Scharf M, Piecha FA, et al. Anti-VGLUT2 autoantibodies in neurological diseases. Brain, Behavior, and Immunity. 2025. doi:10.1016/j.bbi.2025.06.014

BibTeX
@article{Corty2025,
  author = {Corty, Merle and Arlt, Friederike A and Borowski, Kathrin and Wernick, Stephanie and Scharf, Madeleine and Piecha, Fabian A and Steen, Claudia and Oehler, Philipp and Buthut, Maria and Krill, Moritz and Zöllner, Johann-Philipp and Krafft, Tammo and Markewitz, Robert and Radzimski, Christiane and Denno, Yvonne and Probst, Christian and Teegen, Bianca and Grefkes, Christian and Knake, Susanne and Witt, Karsten and Finke, Carsten and Hagemann, Georg and Becker, Jana and Kraemer, Markus and Witte, Torsten and Komorowski, Lars and Wandinger, Klaus-Peter and Prüss, Harald and Melzer, Nico and Miske, Ramona},
  title = {Anti-VGLUT2 autoantibodies in neurological diseases},
  journal = {Brain, Behavior, and Immunity},
  year = {2025},
  doi = {10.1016/j.bbi.2025.06.014}
}
Kostenlos starten →